Literature DB >> 25510566

MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer.

Jianhong Wu1, Guangxin Li, Yongliang Yao, Zeyou Wang, Wangwei Sun, Jianjun Wang.   

Abstract

CONTEXT: The sensitivity and specificity of blood microRNA-421 (miR-421) as a gastric cancer (GC) biomarker has not been determined.
OBJECTIVE: To investigate the diagnostic value of blood miR-421 as GC biomarker.
MATERIALS AND METHODS: miR-421 in serum and peripheral blood mononuclear cells (PBMCs) of 90 GC patients and 90 controls was detected by quantitative real-time PCR. The correlation of miR-421 to GC clinicopathological features as well as the diagnostic value of miR-421 comparing to carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) were analyzed.
RESULTS: miR-421 increased significantly in GC patients than in controls. miR-421 in either serum or PBMCs had higher sensitivity and specificity than CEA and CA-125 in GC diagnosis. The GC positive prediction rates of miR-421 were also significantly higher than those of CEA and CA-125. DISCUSSION AND
CONCLUSIONS: miR-421 in serum or PBMCs may be a new potential diagnostic biomarker for GC.

Entities:  

Keywords:  Cancer antigen 125; MicroRNA-421; carcinoembryonic antigen; gastric cancer; tumor marker

Mesh:

Substances:

Year:  2014        PMID: 25510566     DOI: 10.3109/1354750X.2014.992812

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  27 in total

1.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

Review 2.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

Review 3.  Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review.

Authors:  Ya-Kai Huang; Jian-Chun Yu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  A systematic review of microRNAs as potential biomarkers for diagnosis and prognosis of gastric cancer.

Authors:  Alireza Ahadi
Journal:  Immunogenetics       Date:  2021-01-05       Impact factor: 2.846

Review 5.  WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?

Authors:  Sergiusz Jozwiak; Albert Becker; Carlos Cepeda; Jerome Engel; Vadym Gnatkovsky; Gilles Huberfeld; Mehmet Kaya; Katja Kobow; Michele Simonato; Jeffrey A Loeb
Journal:  Epilepsia       Date:  2017-04-07       Impact factor: 5.864

6.  Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients: A meta-analysis.

Authors:  Yingying Xu; Guiping Wang; Wenqing Hu; Songbing He; Dandan Li; Ping Chen; Jinjie Zhang; Yongshun Gao; Duonan Yu; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

7.  MicroRNA-421 promotes the proliferation and metastasis of gastric cancer cells by targeting claudin-11.

Authors:  Peng Yang; Mei Zhang; Xiting Liu; Huayun Pu
Journal:  Exp Ther Med       Date:  2017-07-17       Impact factor: 2.447

8.  Correlation between microRNA-421 expression level and prognosis of gastric cancer.

Authors:  Haiyan Liu; Yongjian Gao; Defeng Song; Tong Liu; Ye Feng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 9.  Dysregulation of non-coding RNAs in gastric cancer.

Authors:  Qing Yang; Ren-Wen Zhang; Peng-Cheng Sui; Hai-Tao He; Lei Ding
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Improving the Early Diagnosis of Gastric Cancer.

Authors:  Robert J Huang; Joo Ha Hwang
Journal:  Gastrointest Endosc Clin N Am       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.